DIA Biosimilars 2013

PATH

Janssen, PATH collaborate for Rilpivirine

Wednesday, September 25, 2013 12:21 PM

Janssen R&D Ireland has signed a license agreement with PATH for the early development of the human immunodeficiency virus type 1 (HIV-1) medicine rilpivirine in a long-acting injection (depot formulation) as potential pre-exposure prophylaxis (PrEP) against HIV infection.

More... »

Cenduit: Now with Patient Reminders

PATH Malaria Vaccine Initiative and Inovio to accelerate development of malaria vaccines

Monday, January 7, 2013 12:22 PM

The PATH Malaria Vaccine Initiative (MVI), a global program established by international nonprofit organization PATH, and Inovio Pharmaceuticals, a vaccine developer, have agreed to a follow-on collaboration to advance malaria vaccine development and new vaccination delivery technologies.

More... »

CRF Health – eCOA Forum

Novavax, PATH to produce vaccines for low-income countries

Monday, July 23, 2012 11:26 AM

Novavax, a clinical-stage biopharmaceutical company based in Rockville, Md., has partnered with international non-profit organization PATH to develop a vaccine against respiratory syncytial virus (RSV) — the most common cause of childhood respiratory infection globally — for infants in low-income countries with a high disease burden.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.